drugset / Trial / NCT06139952

Ameliorating Contrast Induced Nephropathy After Coronary Angiography

NCT06139952

Phase 4 Completed 120 enrolled Ain Shams University
RandomizedParallel-groupSingle-blindPrevention

Summary

Given the limited understanding of the impact of statin and N-acetyl cysteine use before angiography in preventing contrast-induced nephropathy (CIN), the objective of this study is to evaluate the effectiveness of atorvastatin in preventing CIN among patients undergoing coronary angiography.

Timeline

Start
2023-12-01
Primary completion
2024-03-01
Completion
2024-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 80 mg Oral
Subject N-acetylcysteine Small molecule 200 mg Oral